WO2008016842A1 - Topical skin compositions, their preparation, and their use - Google Patents
Topical skin compositions, their preparation, and their use Download PDFInfo
- Publication number
- WO2008016842A1 WO2008016842A1 PCT/US2007/074551 US2007074551W WO2008016842A1 WO 2008016842 A1 WO2008016842 A1 WO 2008016842A1 US 2007074551 W US2007074551 W US 2007074551W WO 2008016842 A1 WO2008016842 A1 WO 2008016842A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- component
- extract
- skin
- composition
- grapefruit
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/35—Ketones, e.g. benzophenone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/44—Oxidoreductases (1)
- A61K38/446—Superoxide dismutase (1.15)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/35—Ketones, e.g. benzophenone
- A61K8/355—Quinones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
- A61K8/447—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof containing sulfur
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/55—Phosphorus compounds
- A61K8/553—Phospholipids, e.g. lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/66—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/671—Vitamin A; Derivatives thereof, e.g. ester of vitamin A acid, ester of retinol, retinol, retinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/676—Ascorbic acid, i.e. vitamin C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/678—Tocopherol, i.e. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
- A61K2800/522—Antioxidants; Radical scavengers
Definitions
- one tactic has been to use one or more hydroxy acids or retinoic acid to stimulate the re-growth of dermal ceils, without other components.
- This approach is flawed because it does not recognize that aging is caused by the deleterious interaction of multiple agents on the skin, from multiple sources, causing damage to the skin through multiple simultaneous damage pathways.
- More comprehensive studies have found that environmental factors, such as stress, sun exposure, and impurities in food, water, and air, also adversely
- RNS reactive nitrogen species
- ROS reactive oxygen species
- OOS oxidizing species
- ROS species include superoxide (02-), hydrogen peroxide
- OOS peroxy radicals
- R2O2 peroxy radicals
- R2O2 aikyl peroxide
- OH hydroxyl radical
- OR alkoxy radical
- the OOS species include hypohalous acids (HOX) (where X is chloride, bromide, iodide), Z-amines (where Z is either chlorinated or ammoniated amine containing compounds, the reactive nitrogen species ("RNS") nitric oxide (NO), ammonia, cyclooxygenase, phospholipase A2, phospholipase C and transition metals.
- HOX hypohalous acids
- RNS reactive nitrogen species
- the present inventions are directed to compositions that include selected components that provide a defense against the various pathway mechanisms ot free, radicals, reactive oxygen species, reactive nitrogen species, and other oxidizing., species noted above that adversely effect the human body, including the skin.
- the inventions therefore, also include methods for applying the compositions of the invention to the skin, to inhibit the causative factors that adversely effect the skin, and thereby treat and improve the quality of the skin.
- the compositions and methods of this invention are directed to the prevention of the adverse or detrimental effects of free radicals, reactive oxygen species, reactive nitrogen species, and other oxidizing species noted above, on the human body, including the skin.
- the present invention includes various compositions that include at least one anti-free radical component and/or an anti-superoxide component and/or an anti-hydrogen peroxide component and/or an anti-hydroxyf radical component and/or a chain breaking component.
- Embodiments of the present invention include compositions that include a component that aids in cellular energy product and/or a component that aids in collagen synthesis and/or elastin synthesis and/or inhibits their degradation, and/or a component that aids in or provides cellular activity.
- a composition of the present invention that has been found to positively effect one or more of the foregoing factors, includes a citrus component, such as a grapefruit component, such as grapefruit extract, a superoxide dismutase component, a glutathione component, a tetrahydrodiferuloylmethane component and/or a turmeric component, such as a tumeric extract, a bioflavonoid component, such as a citrus bioflavonoid component, a grape component, such as grape seed extract, a green tea component, such as a green tea extract, tocopherol, and/or a tocopheryl derivative such as tocopheryl acetate.
- a citrus component such as a grapefruit component, such as grapefruit extract, a superoxide dismutase component, a glutathione component, a tetrahydrodiferuloylmethane component and/or a turmeric component, such as a tumeric extract
- composition that includes a soybean component, such as a soybean protein component, a rice component, such as rice protein and more particularly hydrolyzed rice protein, and a sunflower seed component, such as a sunflower seed extract.
- a soybean component such as a soybean protein component
- a rice component such as rice protein and more particularly hydrolyzed rice protein
- a sunflower seed component such as a sunflower seed extract.
- a further composition of the present invention includes a centella asiatica component, such as a centella asiatica extract, a corn kernel component, such as a corn kernel extract, a seaweed component, such as a seaweed extract, and ubiquinone (coenzyme Q).
- a centella asiatica component such as a centella asiatica extract
- a corn kernel component such as a corn kernel extract
- a seaweed component such as a seaweed extract
- ubiquinone coenzyme Q
- composition of the present invention includes a rosemary component, such as a rosemary extract, a lecithin component, a ceramide component, such as a ceramide 3 component, a sitosterol component, such as beta sitosterol, a glycerin component, a panthenol component, a proline component, such as L- proline, and a hyaluronate component, such as sodium hyaluronate.
- a rosemary component such as a rosemary extract, a lecithin component, a ceramide component, such as a ceramide 3 component, a sitosterol component, such as beta sitosterol, a glycerin component, a panthenol component, a proline component, such as L- proline, and a hyaluronate component, such as sodium hyaluronate.
- the present invention further includes compositions containing a combination of one or more of each of the foregoing composition components mentioned in the paragraphs above and, more particularly, the active agents contained therein.
- compositions may be applied to the skin for example, by topically applying an amount, such as an effective amount, of one or more of the various compositions according to the invention.
- FIG. 1 is a graph showing the increase in erythema 30 minutes after
- UV exposure on human skin to which formulations were applied.
- FIG. 2 is a graph showing the increase in erythema 10 hours after UV exposure on human skin to which formulations were applied.
- FfG. 3 is a graph showing the effect of samples on procollagen secretion. The data are expressed as the collagen/viability ratio calculated by dividing the amount of procollagen detected in the tissue culture supernatants by WST-1 reduction as an indicator of cellular viability following the exposure period.
- FIG. 4 is a graph showing the effect of samples on elastin secretion.
- FiG. 5 is a graph showing the effect of samples on MMP-1 activity.
- the data are expressed as % control MMP-1 activity.
- the horizontal line denotes
- FIG. 6 is a graph showing the effect of sampfes on MMP-9 activity.
- the data are expressed as % control MMP-9 activity.
- the horizontal line denotes 100% activity.
- FIG. 7 is a graph showing the effect of samples on Elastase activity.
- FlG. 8 is a graph showing the effect of samples on NO production by
- L6 Lt ⁇ ochroman-6
- NT Nutriene tocotrienols
- TQS ⁇ -
- FIG. 9 is a graph showing the effect of samples on lipid staining in
- HEK001 keratinocytes Data are expressed as % control lipid from untreated cells.
- compositions that provide a defense mechanism against a variety of free radicals, reactive oxygen species, reactive nitrogen species, and other oxidizing species on the human body including the skin. These compositions assist in the maintaining and/or improving of the condition of the skin by, for example, increasing energy in cells of the skin and/or inhibiting adverse enzymes and/or maintaining and/or improving the quality and quantity of elastin, collagen, and glycoticiannoglycan in the skin.
- Compositions of the present invention will, generally speaking, include one or more of: a citrus component, such as a grapefruit component, such as a grapefruit extract component, preferably a grapefruit peel extract, and preferably the component of apigenin;
- a glutathione component S ⁇ jJEffi33rroS"ui ⁇ f ⁇ ffiarast-! ⁇ 3r ⁇ por ⁇ t] a glutathione component; a tetrahydrodiferuloylmethane component; a phenolic component, such as a polyphenol component; an essential oil component; an ascorbic acid component; a turmeric component, such as a tumeric extract; a flavonoid component, such as a bioflavonoid component, such as a citrus bioflavonoid; a grape component, such as grape seed extract; a green tea component, such as a green tea extract; tocopherol and/or derivatives thereof, such as tocopheryl acetate; a soybean component, such as a soybean protein component; a rice component, such as rice protein, and more particularly hydrolyzed rice protein; a sunflower seed component, such as sunflower seed extract; an octi ⁇ oxate component, a butyl methoxyd
- a lecithin component a ceramide component, such as ceramtde 3; a beta sitosterol component; a glycerin component; a panthenol component, such as d-panthenof; an adenosine component; a proline component, such as L- proline; a hyaluronate component, such as sodium hyaluronate; a carbohydrate component; a B vitamin component; and a phylate component.
- the term "complex” means an admixture of various ingredients selected to focus around a common theme relating to the health and maintenance of mammalian skin.
- One such complex of ingredients could be focused on mediating effects of reactive oxygen and nitrogen species.
- One particular embodiment of such a composition that is generally useful for its antioxidant property of preventing free radical damage to the skin, thereby protecting against the aging effects from free radical damage, includes the combination of a citrus component, and preferably a citrus component that contains apigenin.
- the citrus component may be derived from lemon, orange, tangerine, grapefruit, peppers, buckwheat, black currents, apricots, cherries, grapes and prunes.
- a preferred citrus component is a grapefruit component, and more particularly, a grapefruit extract that i ⁇ utudes aprge ⁇ in orsimpiy'is apigenin. It has been fou ⁇ tf that citrus components, ano ⁇ in particular citrus components that contain apigenin, such as a fruit extract and, more particularly, a grape fruit extract, inhibit damage caused by the reactive nitrogen species, in particular, nitric oxide (NO) production. The citrus component has been further found to inhibit lipid peroxidation, as well as inflammation caused by free radicals.
- compositions of the present invention that contain a citrus component, and in particular a grape fruit extract component, preferably containing apigenin, have been found to inhibit damage to the skin caused by nitric oxide production and/or lipid peroxidation and/or inflammatory factors such as inflammation caused by free radicals.
- the composition generally further includes a superoxide dismutase component, which inhibits damage to proteins, elastin, collagen, and DNA, caused by superoxides that attack for example, enzymes; and a glutathione component, which inhibits damage caused by hydrogen peroxide.
- compositions may include a phenolic component and/or one or more of the so-called “essential oils'” and/or ascorbic acid (“vitamin C”) and/or tetrahydrodiferuloylmethane, which may, for example, be found in a tumeric component, such as a tumeric extract.
- essential oils' and/or ascorbic acid (“vitamin C)
- tetrahydrodiferuloylmethane tetrahydrodiferuloylmethane
- Further components may include a flavonoid component, such as a bioflavonoid component, such as a citrus bioflavonoid component from, for example, grapefruit, lemon, or orange; and a polyphenol component which may, for example, be found in a grape component, such as grape seed extract, and preferably procyahidolic oligomers, a green tea component, preferably including polyphenols, and particularly epigallocatechin gallate (EGCG), tocopherol, and/or tocopheryl acetate, are each components that inhibit damage caused by hydroxyl radicals which attack lipids.
- a flavonoid component such as a bioflavonoid component, such as a citrus bioflavonoid component from, for example, grapefruit, lemon, or orange
- a polyphenol component which may, for example, be found in a grape component, such as grape seed extract, and preferably procyahidolic oligomers
- a green tea component preferably including polyphenols, and particularly epi
- this composition includes * grapefruit extract in an amount of from about 0.01% to about 1%, superoxide dismutase in an amount of from about 0.0001% to about 0.01%, glutathione in an amount of from about 0.01% to about 1%, tetrahydrodiferuloy methane or a tumeric extract in an amount of from about 0.001% to about 1%, citrus bioflavonoids in an amount of from about 0.001% to about 1%, grape seed extract in an amount of from about 0.001% to about 1%, green tea extract in an amount of from about 0.01% to about 1%, tocopherol in an amount of from about 0.01% to about 2%, tocopheryl acetate in an amount of from about 0.01% to about 5%.
- a composition generally as described above may maintain and/or improve skin quality, thereby maintaining a youthful appearance, by reducing the detrimental effects of one or more of inflammation, lipid peroxidation, and degradation of collagen, elastin, and DNA.
- a composition will generally include a soybean component, such as a soybean protein component, and preferably the isoflavones, such as genistein and daidzein.
- the soybean component has been found to be an inhibitor of the enzyme elastase, which is released to the skin in response to such factors as exposure the UV rays, dryness, and environmental stresses generally.
- the soybean component helps maintain and/or increase firmness and elasticity of the skin, particularly those that derive from the UV rays of sun exposure.
- This embodiment of the composition will generally also include a rice component, such as rice protein, and more particularly a hydrolyzed rice protein, which has an inhibitory effect on the enzyme collagenase.
- the inhibition of collagenase aids in protecting ⁇ crttegerr irr the" skin, thereby maintaining and/or improving the condition of the skin with respect to elasticity, firmness, wrinkling, dryness, and age spots.
- a sunflower seed component such as sunflower seed extract, may also be included in this embodiment.
- the sunflower seed component has been found to act as an anti-glycation factor, and to maintain and/or improve the condition of the skin by delaying the changes that cause collagen to become rigid with age and other detrimental factors discussed above.
- the composition may further include an octinoxate component and/or a butyl meihoxydibenzyoylmethane component.
- this composition includes soybean protein (Glycine Soja) in an amount of from about 0.01% to about 3%, hydrolyzed rice protein in an amount of from about 0.01% to about 3%, sunflower seed extract in an amount of from about 0.01% to about 3%
- soybean protein Glycine Soja
- hydrolyzed rice protein in an amount of from about 0.01% to about 3%
- sunflower seed extract in an amount of from about 0.01% to about 3%
- a further particular embodiment of the present invention is a composition that includes a centella asiatica component, such as centella asiatica extract.
- the centella asiatica component has been found to promote collagen and elastin synthesis, thereby maintaining or improving the firmness, elasticity, and general strength of the skin.
- the primary active constituents are saponins (triterpenoids), that include asiaticoside, madecassoside, and madasiatic acid.
- a corn kernel component such as a corn kernel extract, and more particularly myo-inositol, may be included in this embodiment, and it provides several benefits that include assistance in production and storage of energy in the cell, inhibition of lipid peroxidation, and it is generally a powerful antioxidant.
- Components of corn kernel extract that may separately or in combination be included in a composition, include nitrogenous elements, carbohydrates", B vitamins, trace elements; a ⁇ difor myo-inositol in the form of phylate.
- a seaweed component such as a seaweed extract (e.g., laminaria digitata extract), may be further included in this embodiment and, when included, it assists in increasing intercellular ATP rate and increasing oxygenation of cells and tissues, thereby generally increasing the structure of skin.
- a ubiquinone (coenzyme Q) component may be included and it acts as a coenzyme for various important enzymatic pathways particularly in the production of energy in cells, and optionally with ascorby! tetraisopalmitate.
- this composition includes Centella
- a further particular embodiment of the present invention is a composition that generally provides a hydrolipid matrix to the skin.
- This composition will generally include a rosemary component, such as a rosemary extract, and preferably rosmarinic acid, phenolic diterpenes, camosol, carnosic acid, and/or ursolic acid, or simply is ursolic acid.
- the rosemary extract will preferably be an extract obtained form the leaf of a rosemary.
- the rosemary component will preferably be encapsulated in a liposome to enhance delivery.
- Additional components will generally include one or more of a lecithin component, a ceramide 3 component, a phospholipid such as a beta sitosterol component, a glycerin component, a panthenol component, a proline component, such as L-profine, and a hyaluronate component, such as sodium hyaluronate.
- Subcombinations of components of the above composition will preferably include a rosemary component" s ⁇ cfras a rosemary-extract: and preferably an extract of rosemary feaf, and a lecithin component.
- a further subcombination of the above composition preferably includes a lecithin component, a ceramide 3 component, and a beta sitosterol component, or preferably includes a ceramide 3 component and a beta sitosterol component. This subcombination of the above components also aids in lipid retention and in forming a moisture layer barrier in and on the skin.
- this composition includes rosemary extract in an amount of from about 0.0001% to about 1%, a lipid complex that includes ceramide 3 in an amount of from about 0.001% to about 0.1% and a beta- sistosterol in an amount of from about 0.0001% to about 0.1%, glycerin in an amount of from about 0.1% to about 10%, panthenol in an amount of from about 0.01% to about 1%, proline in an amount of from about 0.001% to about 1%, and sodium hyaluronate in an amount of from about 0.001% to about 5%.
- each of the foregoing compositions and subcombinations may be used alone, or may be used in combination with additional components to form a further new formulation.
- the present invention thus further includes compositions containing a combination of one or more of each of the foregoing composition components in further combination with additional components discussed below.
- compositions of the present invention may also include a cosmeticaily ⁇ rpriarrnaceuticatly acceptab1e ⁇ ca ⁇ rter Co ⁇ ]pon ⁇ ea ⁇ is ⁇ cfifte ⁇ CO ⁇ npositions may be encapsulated, such as in liposomal capsules.
- the complex forms from about 0.01% to about 10% by weight of the total composition, preferably from about 1% to about 7% by weight of the total composition.
- the anti-superoxide component may include those materials having a nti-su peroxide activity and, in particular, those having superoxide dismutase activity. In other words, it includes those components that can catalyze a dismutation reaction.
- SOD superoxide dismutase
- SODs modified by grafting polyalkylene oxide, polyethylene glycol, polysaccharide or acylated groups, salts of SOD, substances containing such SOD products, porphorins and materials with superoxide dism ⁇ tase-like activity.
- SOD superoxide dismutase
- SODs modified by grafting polyalkylene oxide, polyethylene glycol, polysaccharide or acylated groups
- salts of SOD substances containing such SOD products, porphorins and materials with superoxide dism ⁇ tase-like activity.
- the superoxide dismustases described above, as well as the variants and equivalents that a person of skill in the art can deduce from the literature may be suitable as SODs for use in the present invention.
- they can be of differing origins.
- SODs may have application in the present invention are described in U.S. Pat. No. 5,526,507, the contents of which is incorporated herein by reference.
- the SOD may form from about 0.0001% to about 5%, 0.01% to about 5% by weight of the complex. More, preferably, the SOD may be included in the complex in an amount from about 0.1% to about 2% by weight.
- trre anti-hydrogen peroxide component may be a thiol or thiol derivative.
- thiol is to be understood to be an organic compound characterized by the -SH group.
- Thiol derivatives are organic compounds that are either derivatives that retain the -SH group or are thio ethers or thio esters, in which case the -SH group is converted into the -SR group.
- Compounds that are to be understood as being identical to the thiols or thiol derivatives according to the invention are those that are formed by tautomerism, dt- or oligomerization by hydrogen bonding, hydration or other spontaneous rearrangement from the thiols or thiol derivatives. If a derivative is in equilibrium with an isomer by a different type of rearrangement, for example, migration of an alkyl group, this isomer is regarded as being included in the thiols and thiol derivatives of the invention.
- Suitable thiol and thiof derivatives may include captopril, cysteamine, ergothioneine, mercaptopropionylglycine, penicillamine, N-acetylcysteine, S- acetylcysteine, N,S-diacetylcysteine, N.S-diacetylcysteinamide, cysteine ethyl ester, N- acetylcrysteine ethyl ester, S-acetylcysteine ethyl ester, N.S-diacetylcysteine ethyl ester, th ⁇ oglycolic acid, cysteine, homocysteine, glutathione, thioglyceroi, thiomalic acid,
- 2-mercaptopropionic acid 3-mercaptopropionic acid, thiodiglycoi, 2-mercaptoethanol, dithioreitof, thioxanthene, thiosalicylic acid, thiolactic acid, thiopropionic acid, thiodiglycolic acid, lipoic acid, and cosmetically acceptable salts thereof.
- the cosmetically acceptable salts include, but are not limited to alkali metal salts, e.g., sodium, iithium, potassium, and rubidium salts; alkaline earth metal salts, e.g., magnesium, calcium, and strontium salts; non-toxic heavy metal salts, e.g., atumi ⁇ um and zinc saltsy- b ⁇ rorr salts; silicon saltst ammonium salts; trralkylammonium salts, e.g., trimethyiammonium and triethylammonium, and tetraalkylonium salts.
- alkali metal salts e.g., sodium, iithium, potassium, and rubidium salts
- alkaline earth metal salts e.g., magnesium, calcium, and strontium salts
- non-toxic heavy metal salts e.g., atumi ⁇ um and zinc saltsy- b ⁇ rorr salts
- the anti-hydrogen peroxide component may be incorporated into the complex in an amount from about 0.001% to about 5% by weight, preferably from about 0.01% to about 2.5%, more preferably from about 0.1% to about 1% by weight of the complex.
- anti-hydroxyl radical components can include one or more of the following: tocopherol, tocopherol derivatives, tetrahydrodiferuioylmethane, grape seed extract (e.g., vitis vinifera (grape) seed extract), grape fruit extract (e.g., citrus grandis (grapefruit) fruit extract), green tea extract (e.g., camellia sinensis (leaf) extract), turmeric acid, curcuminoids, tetrahydrocurcuminoids catechins, epigallocatechin 3-0- gatiate and polyphenols, oiigomeric proanthocyanidins, bioflavonoids, flavonoids, and mixtures thereof.
- grape seed extract e.g., vitis vinifera (grape) seed extract
- grape fruit extract e.g., citrus grandis (grapefruit) fruit extract
- green tea extract e.g., camellia sinensis (leaf) extract
- turmeric acid e.g
- Tocopherol (Vitamin E) and its derivatives such as esters of tocopherol are useful in the composition of the present invention.
- Suitable tocopherols include the monomethyl, dimethyl, or triethyl derivatives of tocol, including but not limited to, alpha tocopherol, beta tocopherol, gamma tocopherol, delta tocopherol, epsilon tocopherol, zeta tocopherol, and eta tocopherol.
- Suitable esters of tocopherol include but are not limited to tocopheryl acetate, tocopheryl succinate, tocopheryl benzoate, tocopheryl propionate, tocopheryl sorbate, tocopheryl oleate, tocopheryl orotate, tocopheryl linoleate, tocopheryl nicotinate, and the 2-ethyl-hexanoate ester.
- tocopherol and/or its derivatives are included in the complex of the present invention, they are used at levei-fr ⁇ rab ⁇ ot 0.01% to abo ⁇ t- @ 8%, preferably from about 0.01% to about 5%, and from 0.01% to about 2%.
- Tetrahydrodiferuloylmethane and/or turmeric extract may also be incorporated into the complex at levels from about 0.1% to about 20% by weight of the complex, preferably from about 1% to about 10% by weight.
- grape seed extract and complexes of grape seed extract with phospholipids may also be beneficial for use in the present invention.
- the extracts from grape seed include a mixture polyphenols such as epicatechin, proanthocyanidins, and catechins.
- a suitable complex of grape seed extract and phospholipid is described in U.S. Pat. No. 4,963,527, the contents of which are incorporated herein by reference.
- the grape seed extract or its complex with phospholipids is present in an amount from about 0.001% to about 5% by weight of the complex, preferably from about 0.01% to about 2.5% by weight.
- Green tea extract may be included in the same amounts as the grape seed extract.
- Flavonoids and bioflavonoids may also be useful in the present invention. It has been reported in Bravo, Polyphenols: Chemistry, Dietary Sources, Metabolism, and Nutritional Significance, Nutrition Reviews, Vol. 56, No. 11 , 317-33 (November, 1998), the contents of which are incorporated herein by reference, that flavonoids may be subdivided into 13 classes shown below:
- Ftavonoids have, in general, the common structure of diphenylpropanes (C6-C3-C6) and consist of two aromatic rings linked through three carbons that usually form an oxygenated heterocycte,
- the baste structure is shown below:
- Flavonoids occasionally occur in plants as aglycones, although they are most commonly found as glycoside derivatives.
- the flavonoids may be derived from any suitable source. A preferred source is from citrus.
- flavonoids When flavonoids are incorporated into the complex, they are present at a level from about 0.001% to about 20% by weight of the complex, preferably from about 0.01% to about"! 0% by weight.
- palmitoyi hydroxypropyltrimonium amylopectin can be mixed with camellia sinensis extract. This may be present in amounts ranging from about 0.001% to about 2% by weight of the complex.
- the chain breaker may include the same components as those described above for the anti-hydroxyi radical component.
- one or more of the above anti-hydroxyf radical components may also serve as a chain breaker component.
- Chain breaking antioxidants are those components that can break the chain reaction once lipid peroxidation is initiated.
- the complex composition may also include components selected to repair the damage caused by the ROS.
- the compositions of the present invention includes at least one component that provides cellular energy production, at least one component that aids collagen synthesis, and/or at least one component that aids or provides cellular activity. These components may be used singly or, desirably, in combination.
- a desirable cellular energy production component includes the ubiquinones.
- Ubiquinones are widely found in bacteria, fungi, yeasts, plants, and animals. It is known that different species produce isoforms (Q-n) with different numbers of isoprene units (n). For example, the number of rsoprene units is 6 (Q6) in some microorganisms, nine (Q9) in plants, and ten (Q10) in humans.
- Coenzyme Q10 or 2 I functions ⁇ to recover and maintain respiration and promotes ATP production in terms of energy supply for cellular activities. Derivatives of the ubiquinones such as ubiquinols may atso be useful
- the cellular energy production component for example, coenzyme
- Q10 is incorporated into the complex in an amount ranging from about 0.001% to about 10%, preferably from about 0.01% to about 5% by weight of the complex.
- hydroxy acids including alpha and beta hydoxy acids may be useful in this regard.
- the present invention contemplates including one or more alpha or beta hydroxy acids. Suitable examples include lactic, malic, glycolic, citric, and salicylic acid.
- ascorbic acid Vitamin C
- its derivatives promote collagen synthesis.
- the ascorbic acid derivative useful in the present invention includes all enantiomers whether singly or in combination.
- the ascorbic acid is provided in the levo form.
- the ascorbic acid or its derivatives may be in a water soluble or an oil soluble form.
- the vitamin C (ascorbic acid) derivatives are, for instance, the alkyf esters of L-ascorbic acid where the aikyl portion has from 8 to 20 carbon atoms. With respect to the esters, they may be selected from the group consisting of fatty acid mono-, di- ⁇ tri- or tetra-esters of ascorbic acid.
- esters include, but are not limited to ascorbyl palmitate, ascorbyl laureate, ascorbyl my ⁇ state, ascorbyl stearate, ascorbyl dipalmitate, ascorbyl dtlaurate, ascorbyl dimyristate, ascorbyl distearate, ascorbyl tripalmitate, ascorbyl trilaurate, ascorbyl trimyristate, ascorbyl iristearate; ascorbyl tetrapahnitate (tetrahexyldecyl asc ⁇ rbate),' ascorbyl tetralaurate, ascorbyl tetramyristate, ascorbyl tetrastearateL-ascorbyl palmitate, L-ascorbyl isopalmitate, L-ascorbyl dipalmitate, L-ascorbyi isostearate, L- ascorbyl distearate, L-ascorbyl di
- the salts may be selected from the phosphates and sulfates, preferably phosphate.
- the ascorbic acid phosphate is generally selected from L-ascorbic acid 3-phosphate, L-ascorbic acid 2-phosphate, L-ascorbic acid 3- pyrophosphate and bis (L-ascorbic acid 3,3-) phosphate.
- the ascorbic acid phosphate is magnesium or sodium ascorbyl phosphate; more preferably, magnesium ascorbyl phosphate.
- the ascorbic acid sulfate is generally selected from L- ascorbic acid 3-sulfate, L-ascorbic acid 2-sulfate, L-ascorbic acid 3-pyrosulfate and bis
- the collagen synthesis component for example, the ascorbic acid and its derivatives, is incorporated in the complex in an amount ranging from about 0.001% to about 10%, preferably from about 0.01% to about 5% by weight of the complex.
- retinoids may affect cellular activity and thus it is desirable to incorporate retinoids in the complex of the present invention.
- the retinoids include retinol; retinal (Vitamin A aldehyde), and retinyl esters such as retinyl acetate, retinyl butyrate, retinyl propionate, retinyl octanoate, retinyl laurate, retinyl palmitate, retinyi oleate, and retinyi linoteate.
- Retinoids tend to irritate the skin and therefore, it is desirable to incorporate them in the complex at levels so as to minimize the potential irritation.
- irrttancy mitiga ⁇ ts may be incorporated into the compositions to assist in preventing undue discomfort to the user while potentially permitting the dosage level of retinoid to be increased.
- irritancy mitigants include, but are not limited to ceramides, pseudoceramides, fatty acids, cholesterol, phospholipids, panthenol, oat extract, allantoin, ginkgo biloba, licorice extract, calendula, ginseng, butchers broom, and the like.
- the cellular activity component for example, the retinoid, is incorporated in the complex at a level ranging from about 0.001% to about 10%, preferably from about 0.01% to about 5% by weight of the complex.
- the complex compositions according to the present invention are generally mixed with a pharmaceutically or cosmetically acceptable vehicle or carrier.
- the complex compositions of the present invention may be formulated as a solution, gel, lotion, cream, ointment, oil-in-water emulsion, water-in-oil emulsion, or other pharmaceutically or cosmetically acceptable form.
- the complex compositions of the present invention may also contain various known and conventional cosmetic components so long as they do not detrimentally affect the desired effects.
- the pharmaceutically acceptable or cosmetically acceptable vehicle acts as a dilutant, dispersant, or carrier for other materials present in the complex composition, so as to facilitate their distributiorr when r the complex composition- is- applied to the skin.
- Vehicles other than water can include liquid or solid emollients, solvents, humectants, thickeners, and powders.
- the following vehicles can be used alone or as a combination of one or more vehicles.
- Vehicles may also include propellants such as propane, isobutane, dimethyl ether, carbon dioxide, nitrous oxide; and solvents such as ethyl alcohol, isopropanol, acetone, ethylene glycol monomethyl ether, diethylene glycol monobutyl ether, diethylene glycol monoethyl ether, or powders such as chalk, talc, fullers earth, kaolin, starch, gums, collodial silica, sodium polyacrylate, tetra aikyl and/or trialkyl aryl ammonium smectites, chemically modified magnesium aluminum silicate, organically modified montmorillonite clay, hydrated aluminum silicate, fumed silica, carboxyvinyl polymer, sodium carboxymethyl cellulose, ethylene glycol monostearate.
- propellants such as propane, isobutane, dimethyl ether, carbon dioxide, nitrous oxide
- solvents such as ethyl alcohol, isopropanol, ace
- Emollients such as stearyl alcohol, glyceryl monoricinoleate, mink oil, cetyl alcohol, isopropyl isostearate, stearic acid, isobutyl palmitate, isocetyl stearate, oleyl alcohol, isopropyl laurate, hexyi laurate, decyi oleate, octadecan-2-ol, isocetyl alcohol, eicosanyl alcohol, behenyi alcohol, cetyl palmitate, silicone oils such as dimethylpolysiloxane, di-n-butyl sebacate, isopropyl myristate, isopropyl palmitate, isopropyl stearate, butyl stearate, polyethylene glycol, triethylene glycol, lanolin, cocoa butter, corn oil, cotton seed oil, olive oil, palm kernel oil, rapeseed oil, safflower seed oil, evening primrose oil
- emollients refer to materials used for the prevention or relief of dryness, as well as for the protection of the skin.
- suitable emollients are known and may be used herein. Sagarin, Cosmetics, Science and
- composition can optionally comprise sunscreens such as inorganic and organic sunscreens to provide protection from the harmful effects of excessive exposure to sunlight during use of the complex composition of the present invention.
- sunscreens such as inorganic and organic sunscreens to provide protection from the harmful effects of excessive exposure to sunlight during use of the complex composition of the present invention.
- suitable sunscreens include those described in the U.S. OTC
- Sunscreen Monograph such as octinoxate, and butyl methoxy dibenzoylmethane, the contents of which is incorporated herein by reference.
- composition of the invention can accordingly comprise from 0.1 to
- the composition optionally can also comprise as a sunscreen titanium dioxide or zinc oxide having an average particle size of from 1 to 300 nm, iron oxide having an average particle size of from 1 to 300 nm, silica, such as fumed silica haying an average particle size of from 1 to 100 ⁇ m.
- a sunscreen titanium dioxide or zinc oxide having an average particle size of from 1 to 300 nm
- iron oxide having an average particle size of from 1 to 300 nm
- silica such as fumed silica haying an average particle size of from 1 to 100 ⁇ m.
- silica when used as an component in the emulsion according to the invention can provide protection from infrared radiation.
- UUrafine titanium dioxide in either of two forms namely water- dispersible titanium dioxide and oil-dispersible titanium dioxide may be used.
- Water- dispersible titanium dioxide is ultrafine titanium dioxide, the particles of which are tmcoated or which are coated with a material to rmpa ⁇ ta"hyd ⁇ ophilic surface property-ftr the particles. Examples of such materials include aluminum oxide and aluminum silicate.
- Oil-dispersible titanium dioxide is ultrafine titanium dioxide, the particles of which exhibit a hydrophobic surface property, and which, for this purpose, can be coated with metal soaps such as aluminum stearate, aluminum laurate, or zinc stearate, or with organosilicone compounds.
- titanium dioxide particles of titanium dioxide having an average particle size of less than 100 nm, preferably from 10 to 40 nm and most preferably from 15 to 25 nm.
- the total amount of titanium dioxide that can optionally be incorporated in the composition according to the invention is from 1 to 25%, preferably from 2 to 10% and ideally from 3 to 7% by weight of the composition.
- a particularly convenient form of the composition is an emulsion, in which case an oil or oi!y material (emollient) will normally be present, together with an emulsifier to provide either a water-in-oil emulsion or an oil-in-water emulsion.
- the composition can also comprise water, usually up to 95%, preferably from 5 to 95% by weight.
- the composition can also optionally comprise a high molecular weight silicone surfactant that can also act as an emulsifier, in place of or in addition to the optional emulsifier(s) already mentioned.
- the silicone surfactant may be a high molecular weight polymer of dimethyl polysiloxane with polyoxethyiene and/or polyoxpropylene side chains having a molecular weight of from 10,000 to 50,000.
- the dimethyl potysiloxane polymer is conveniently provided as a dispersion in a volatile siioxane, the dispersion comprising, for example, from 1 to 20% by volume of the polymera ⁇ Hr ⁇ 80 to 99% by volume of the volatile siioxane.
- the dispersion consists of a 10% by volume of the polymer dispersed in the volatile siioxane.
- Examples of the volatile siloxanes in which the polysiloxane polymer can be dispersed include polydimethyt siioxane (pentamer and/or hexamer).
- a preferred silicone surfactant is cyclomethico ⁇ e and dimethicone copolyol, such as DC 3225C Formulation Aid available from DOW CORNING.
- Another is laurylmethicone copolyol, such as DC Q2-5200, also available from Dow Corning.
- the amount of silicone surfactant, when present in the composition will normally be up to 25%, preferably from 0.5 to 15% by weight of the emulsion.
- adjuncts examples include preservatives, such as para-hydroxy benzoate esters; antioxidants, such butyl hydroxy toluene; humecta ⁇ ts, such as glycerol, ethoxylated glycerins such as glycereth- 26, sorbitol, 2-pyrrolidone-5-carboxylate, dibutylphthalate, gelatin, polyethylene glycol, such as PEG 200-600; buffers together with a base such as triethanolamine or sodium hydroxide; waxes, such as beeswax, ozokerite wax, paraffin wax; plant extracts, such as Aloe Vera, cornflower, witch hazel, elderflower, cucumber; as well as acerola cherry fermentate, thickeners; activity enhancers; colorants; and a fragrance, such as perfumes, may be included in a composition prepared in accordance with the present invention.
- preservatives such as para-hydroxy benzoate esters
- antioxidants such buty
- Cosmetic adjuncts can form the balance of the composition.
- anti-inflammatory and/or anti-irritant agents can be used.
- the natural anti-inflammatory and/or anti-irritant agents are preferred.
- licorice and its extracts, dipotassium glycyrrhizinate, oat and oat extracts, cande ⁇ lla wax, alpha bisabolot, aloe vera, Ma ⁇ jistha (extracted from plants in the-gentis Rubia, particularly Rubia cordifoliai), and Guggal (extracted from plants in the genus Commiphora, particularly Commiphora Mukul), may be used.
- Skin conditioning agents that may be included, as mentioned above, are hyaluronic acid, its derivatives and salts including sodium hyaluronate, plant extracts such as kola nut, guarana mate, algae extract, proline, L-proline, and skin benefit agents such as ceramides, glycoceramides, pseudoceramides, sphingolipids such as sphingomyelins, cerebrosides, suiphatides, and ganglioside, sphingosines, dihydrosphingosine, phytosphingosines, phospholipids, either separately or in mixtures. Fatty acids may also be combined with these skin benefit agents.
- compositions according to the present invention may be prepared in accordance with conventional procedures that are known in the art.
- components of the present invention may be combined by sequential addition, with or without preference to order, followed by mixing to form a mixture.
- compositions may be prepared by admixing, suchras'irrar ⁇ ne ⁇ pOt system.
- the compositions of the present invention may be administered to an individual, preferably by topical application to the skin of the individual.
- the compositions may be applied in an amount effective to inhibit free radicals, reactive oxygen species, and other oxidizing species.
- compositions of the present invention may be applied to the skin in an amount of about 1 mg/cm 2 to about 3 mg/cm 2 of skin.
- the compositions of the present invention will be applied in an amount of about 2 mg/cm 2 per square inch of skin.
- the composition should be applied twice a day, such as in the morning and in the evening.
- compositions preferably include components for enhancing the transportation of the active components into the epidermal and dermal layers of the skin.
- Such components include dimethyl sulfoxide (DMSO) or n-decylmethyl sulfoxide (NDMS).
- Samples were diluted in media. RON SBD 101 , Centella asiatica, and vitamin C were prepared at 0.001, 0.01, and 0.1% concentrations. The remaining samples were prepared at 0.1, 1, and 10% concentrations. Centeila asiatica was prepared as an extract in DMSO:ethanol:water at 50:30:20. Human dermal fibroblasts (Hs-27) were plated in 24 well plates and were incubated overnight. The following day, the cells were treated with the samples at the concentrations previously indicated. Supernatant fluids were collected and tested for the presence of procollagen using a commercially available ELISA kit and elastin using the Fastin Elastin kit.
- the levels of collagen produced by the cells are shown in figure 3. Collagen synthesis is expressed as a ratio of the amount of procollagen detected divided by viability to allow for any toxic effects of the samples.
- the data demonstrate that the Centelia asiatica sample was most potent at inducing new collagen synthesis at a concentration of 0.1%.
- the Biopeptide CL and Biopeptide EL samples also induced a detectable increase in collagen synthesis at a concentration of 10%. The other samples had no detectable effect on procollagen synthesis.
- the data in figure 4 show the effect of the samples on elastin secretion.
- the data are again expressed as the ratio of the amount of elastin secreted divided by the viability of the cells at the time of supernatant collection.
- the Centella asiatica sample was the most potent inducer of etastin.
- Biopeptide CL and Biopeptide EL also induced detectable increases in elastin secretion.
- the Odraline and Biodynes EMPP samples induced slight increases in elastin at the highest concentration used (10%).
- Centella asiatica is a potent inducer of both collagen and efastin. Additionally, the results suggest that the Biopeptide CL & EL samples induced both collagen and elastin although a high concentration of these materials is needed in order to induced the observed biological effect.
- MMPs matrix metalloproteinases
- elastase The strongest inhibitors of elastase were Collalift, Alphinia leaf, Elhibin, Sophorine, Lemon bioflavonoids, ACTIMP 1.3.9, Lemon and mixed citrus extracts, Keipadelpie, Extraceflium, and Colhibin. Therefore, base on the desired profile of MMP- 1 and etastase inhibition while having no effect of MMP-9, elhibin would be the raw material of choice.
- MMP matrix metalloproteinases
- such a skin care product should not inhibit MMP- ⁇ as this would potentially inhibit synthesis of new collagen synthesis by blocking availability of collagen building blocks.
- elastase should be inhibited as to prevent digestion of elastin and the resulting elasticity of the skin.
- the data in Table I below gives information regarding the source and solubility for each of the samples tested.
- the data in Figure 5 demonstrate the effect of the samples on MMP-1 activity. Elhibin was the only sample that inhibited MMP-1.
- the data in Figure 6 demonstrate that most of the samples did not inhibit MMP-9.
- the only sample with strong inhibitory activity for MMP-9 was BVOSC ester.
- the data in Figure 7 demonstrate that a number of the samples inhibited elastase. These samples were Colla ⁇ ft, Alphinia leaf, Elhibin, Sophorine, ACTIMP 1.3.9, Lemon and mixed citrus extracts, Kelpadelpie, Extracellium, and Colhibin.
- kits were used for testing the effect of the samples on the activity of the MMPs of interest.
- MMP-1 a kit from Amersham was used according to the manufacturer's specifications.
- MMP-9 and Elastase kits from Molecular Probes were used.
- the samples were prepared in the solvent noted in table I at stock concentrations of 100 mg/ml.
- the samples were diluted to 100 mg/ml using PBS.
- EXAMPLE 3 Cells in skin can produce nitric oxide (NO) when exposed to UV light, and NO thus produced has the potential to induce age associated changes in skin.
- NO nitric oxide
- This study was performed in order to screen a panel of cosmetics and skin care raw materials for their effect on NO production by RAW 264.7 cells.
- the murine macrophage cell line RAW 264.7 was used in the study as it has been shown to produce NO when stimulated with LPS.
- Murine RAW 264.7 cells were seeded in a 96 well plate at 1 X 10 s cells /weih The plate was incubated overnight. The following day, the cells were treated- with the samples at 0.001, 0.01, and 0.1% for 2 hours. The samples are listed below in Table II. Following the exposure period, LPS was added to the wells at 100 ng/ml. The plate was incubated overnight. Equal volumes of culture supernatant and Griess reagent were incubated for 15 min at room temperature and the absorbance at 540 nm was read. The amount of nitrite in the samples was calculated from a standard curve generated with sodium nitrite.
- Table III NO production by RAW 2647 cells stimulated with LPS. Data are shown as ng nitrite/ml supernatant.
- Hyaluronic acid is a member of the glycosaminoglycan family of compounds. Giycosami ⁇ oglycans make up the ground substance of connective tissue, and along with elastin, help provide elasticity to skin. They also hold water and therefore provide viscosity and hydrating properties.
- Centella asiatica and vitamin C were prepared at 0.001%.
- Biodynes EMPP was prepared at 0.1%.
- Centella asiatica was prepared as an extract in DMSO:ethanol:water at 50:30:20.
- the "energy booster" samples Seanergilium algae extract, Thiotaine, Sepitonic, and Phytovityl corn kernel extract, were all prepared in media at 0.01, 0.1, and 1.0%.
- Human dermal fibroblasts (Hs-27) were plated in 24 well plates and were incubated overnight. The ceils were treated with the samples at the concentrations indicated for 2 consecutive days.
- Table IV Effect of samples on procollagen secretion. Data are expressed as ng/ml procollagen/ml supernatant calculated from a standard curve generated with the procollagen standard provided with the ELlSA kit.
- Table V Effect of samples on elastin secretion. Data are expressed as the % media control elastin calculated by dividing the amount of elastin in detected in the tissue culture supematants from treated cells by the amount of elastin secreted by untreated control cells.
- Table IV shows the effect of samples on hyaluronic acid secretion. Data are expressed as ng hyaluronic acid/ml culture supernatant. The amount of hyaluronic acid in each supernatant was calculated from a standard curve generated using a hyaluronic acid standard supplied with the ELISA kit.
- the Sepitonic or Phytovityl materials may be valuable for skin applications where an increase in hyaluronic acid, and subsequently increased hydration, is desired.
- Human HEK001 cells were plated at 2 X 10 4 /wel ⁇ in 96 well plates and were incubated overnigtrt: The-fotiowirig day, trr ⁇ -eettr were- exposed to the samptes that had been diluted into cell culture media at 0.005%, 0.05%, and 0.5%. The cells were then again incubated overnight. The following day, the cells were fixed in 1% formaldehyde. Cellular lipids were then stained with Oil Red O stain (1). Following staining, the lipid bound stain was extracted with isopropanol. The OD of the extracted stain was read at 515 ⁇ m.
- composition that can be prepared according to a further embodiment of the present invention.
- composition provides a defense against ROS and also includes components to help repair damage caused ROS.
- composition provides a defense against ROS and also includes components to help repair damage caused ROS.
- UV radiation and the skin erythema was measured.
- FIGS, 1 and 2 show the results.
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/497,152 US20070003536A1 (en) | 2000-11-21 | 2006-07-31 | Topical skin compositions, their preparation, and their use |
US11/497,152 | 2006-07-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2008016842A1 true WO2008016842A1 (en) | 2008-02-07 |
Family
ID=38705066
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2007/074551 WO2008016842A1 (en) | 2006-07-31 | 2007-07-27 | Topical skin compositions, their preparation, and their use |
Country Status (4)
Country | Link |
---|---|
US (3) | US20070003536A1 (en) |
KR (1) | KR20090040344A (en) |
CN (2) | CN101522265A (en) |
WO (1) | WO2008016842A1 (en) |
Families Citing this family (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MXPA06008293A (en) * | 2004-01-22 | 2007-06-11 | Univ Miami | Topical co-enzyme q10 formulations and methods of use. |
US20090076132A1 (en) * | 2005-03-11 | 2009-03-19 | Gary Pekoe | Antiviral compositions and methods of treatment |
US20080166426A1 (en) * | 2005-03-11 | 2008-07-10 | Gary Pekoe | Anitbacterial compositions and methods of treatment |
CA2823407C (en) | 2007-03-22 | 2016-10-18 | Berg Pharma Llc | Topical formulations having enhanced bioavailability |
WO2008130752A2 (en) | 2007-04-19 | 2008-10-30 | Mary Kay Inc. | Magnolia extract containing compositions |
FR2915379B1 (en) * | 2007-04-27 | 2012-07-13 | Vincience | USE OF AN ACTIVE INGREDIENT FROM RICE (ORYZA SATIVA L) FOR PREPARING A COMPOSITION INTENDED TO PROTECT MITOCHONDRIA |
FR2915382B1 (en) * | 2007-04-27 | 2012-06-01 | Vincience | USE OF AN ACTIVE INGREDIENT FROM MAIZE (ZEA MAYS L) FOR PREPARING A COMPOSITION INTENDED TO ACTIVATE CYTOCHROME C |
FR2915380B1 (en) * | 2007-04-27 | 2012-06-08 | Vincience | USER OF AN ACTIVE INGREDIENT FROM RICE (ORYZA SATIVA L) FOR PREPARING A COMPOSITION INTENDED TO ACTIVATE CYTOCHROME C |
US9750681B2 (en) | 2007-04-27 | 2017-09-05 | Jg Skin, Inc. | Skin care composition |
FR2915383B1 (en) * | 2007-04-27 | 2010-01-15 | Vincience | USE OF AN ACTIVE INGREDIENT FROM RICE (ORYZA SATIVA L.) FOR PREPARING A COMPOSITION FOR ACTIVATING CELL ENERGY AND PROTECTING THE SKIN FROM OXIDATIVE DAMAGE. |
FR2918569B1 (en) * | 2007-07-09 | 2012-09-28 | Engelhard Lyon | SUBSTANCES INHIBITING GLYCATION OF PROTEINS. |
DE102007037772A1 (en) * | 2007-08-10 | 2009-02-12 | Csabai, Zsolt, Dr. Ph. | Antioxidant complex based on Grape Vital (citrus and / or grape seed and / or flavonoid base) |
GB0719202D0 (en) * | 2007-10-02 | 2007-11-07 | Boots Co Plc | Compositions and methods for the skin and hair |
DE102007055008A1 (en) * | 2007-11-14 | 2009-06-10 | Coty Prestige Lancaster Group Gmbh | Cosmetic product for the protection of the skin against environmental influences |
JP2011511770A (en) * | 2008-01-25 | 2011-04-14 | シェーリング−プラウ ヘルスケア プロダクツ,インコーポレイテッド | Method for selecting antioxidants for use in topically applied compositions |
KR20100136997A (en) | 2008-04-11 | 2010-12-29 | 싸이토테크 랩스, 엘엘씨 | Methods and use of inducing apoptosis in cancer cells |
US9445975B2 (en) * | 2008-10-03 | 2016-09-20 | Access Business Group International, Llc | Composition and method for preparing stable unilamellar liposomal suspension |
US8178106B2 (en) * | 2009-03-30 | 2012-05-15 | Mary Kay Inc. | Topical skin care formulations |
US20100260695A1 (en) * | 2009-04-09 | 2010-10-14 | Mary Kay Inc. | Combination of plant extracts to improve skin tone |
MX2011011958A (en) | 2009-05-11 | 2012-02-13 | Berg Biosystems Llc | Methods for treatment of metabolic disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers. |
US20110081430A1 (en) | 2009-10-02 | 2011-04-07 | Simarna Kaur | COMPOSITIONS COMPRISING AN NFkB-INHIBITOR AND A TROPOELASTIN PROMOTER |
US8084504B2 (en) | 2009-10-02 | 2011-12-27 | Johnson & Johnson Consumer Companies, Inc. | High-clarity aqueous concentrates of 4-hexylresorcinol |
US8906432B2 (en) * | 2009-10-02 | 2014-12-09 | Johnson & Johnson Consumer Companies, Inc. | Compositions comprising an NFκB-inhibitor and a non-retinoid collagen promoter |
US8337870B2 (en) * | 2009-12-15 | 2012-12-25 | Young Pharmaceuticals, Inc. | Low toxicity topical active agent delivery system |
EP2544663B1 (en) | 2010-03-12 | 2018-01-03 | Berg LLC | Intravenous formulations of coenzyme q10 (coq10) and methods of use thereof |
AU2011227198A1 (en) * | 2010-03-17 | 2012-10-04 | Arbonne International Llc | Topical skin care composition |
EP2422735A1 (en) | 2010-08-27 | 2012-02-29 | ECP Entwicklungsgesellschaft mbH | Implantable blood transportation device, manipulation device and coupling device |
KR101933732B1 (en) | 2011-04-04 | 2018-12-28 | 버그 엘엘씨 | Methods of treating central nervous system tumors |
WO2012142511A2 (en) * | 2011-04-15 | 2012-10-18 | Md Matrix Health Llc Dba Md Matrix Health Inc | Orthomolecular compositions and their use in stabilizing the extracellular matrix |
SG10201605008TA (en) | 2011-06-17 | 2016-07-28 | Berg Llc | Inhalable pharmaceutical compositions |
DE102011109546A1 (en) * | 2011-08-03 | 2013-02-07 | Evonik Goldschmidt Gmbh | Use of sphinganine to improve the visual appearance of the skin and hair |
CN102366371B (en) * | 2011-10-25 | 2013-07-10 | 西北农林科技大学 | Patched grape pip facial mask and preparation method thereof |
CN102406581B (en) * | 2011-11-28 | 2013-01-30 | 天津郁美净集团有限公司 | Skin protecting composite with function of tightening skin |
WO2013089533A1 (en) * | 2011-12-16 | 2013-06-20 | 주식회사 아모레퍼시픽 | Composition containing tangeretin for external application to the skin |
KR102142311B1 (en) * | 2011-12-16 | 2020-08-10 | (주)아모레퍼시픽 | Skin external composition comprising tangeretin |
WO2013096639A1 (en) | 2011-12-20 | 2013-06-27 | The Procter & Gamble Company | Human skin sample methods and models for assessing tone-specific benefits of agents |
KR20130088912A (en) * | 2012-01-31 | 2013-08-09 | (주)아모레퍼시픽 | Skin external composition containing tangeretin and egcg |
ITRM20120121A1 (en) * | 2012-03-27 | 2013-09-28 | Aboca Spa Societa Agricola | DERMOPROTECTIVE AND DERMO-BALANCING COMPOSITION. |
US20140004210A1 (en) * | 2012-06-28 | 2014-01-02 | Shiseido Company, Ltd. | Degradation inhibitor of hyaluronic acid, comprising rosemary extract and retinol acetate |
CN103520013A (en) * | 2012-07-04 | 2014-01-22 | 江苏天晟药业有限公司 | Skin-whitening and freckle-removing formula and preparation method for gel thereof |
US20140086859A1 (en) | 2012-09-24 | 2014-03-27 | Johnson & Johnson Consumer Companies, Inc. | Low oil compositions comprising a 4-substituted resorcinol and a high carbon chain ester |
WO2014074592A1 (en) * | 2012-11-08 | 2014-05-15 | University Of Florida Research Foundation, Inc. | Seaweed extracts, unsaturated fatty acids, and methods of treatment |
WO2014137231A2 (en) * | 2013-03-07 | 2014-09-12 | T2G Biotechnology Limited | Totarol extract formulations and uses thereof |
EP2983654A4 (en) | 2013-04-08 | 2016-11-30 | Berg Llc | Treatment of cancer using coenzyme q10 combination therapies |
SG10201907816RA (en) | 2013-09-04 | 2019-09-27 | Berg Llc | Methods of treatment of cancer by continuous infusion of coenzyme q10 |
US10123965B2 (en) * | 2014-07-30 | 2018-11-13 | Younique, Llc | Formulations, methods and devices for periorbital skin rejuvenation |
CN104727520A (en) * | 2015-02-28 | 2015-06-24 | 孙小力 | Reinforced floor manufactured by soybean protein glue and manufacturing method |
AU2016235861B2 (en) * | 2015-03-26 | 2018-07-19 | Elc Management Llc | Compositions for increasing the lipid content of keratinocytes |
KR102036532B1 (en) * | 2015-04-09 | 2019-10-25 | 아이에스피 인베스트먼츠 엘엘씨 | Cosmetic treatment methods to protect skin from contamination and improve skin regeneration |
KR102139659B1 (en) * | 2015-12-08 | 2020-07-30 | 주식회사 엘지생활건강 | Composition for improving the skin |
FR3049858B1 (en) * | 2016-04-12 | 2019-05-24 | Activ'inside | USE OF A COMPOSITION COMPRISING SOD AND VITAMIN C FOR ANTI-AGE COSMETIC EFFECT |
WO2018081005A1 (en) | 2016-10-25 | 2018-05-03 | Access Business Group International Llc | Compositions of lithospermum erythrorhizon (gromwell root) and methods of making and using the compositions |
US11020357B2 (en) | 2018-03-19 | 2021-06-01 | Alexandra Yerike | Compound for use in relief of pain and method to produce thereof |
WO2019192694A1 (en) | 2018-04-05 | 2019-10-10 | Beiersdorf Ag | Anti-pollution shield |
US10980851B2 (en) * | 2018-06-08 | 2021-04-20 | The Procter & Gamble Company | Topical skincare compositions comprising Centella asiatica selected triterpenes |
CN108853312B (en) * | 2018-09-25 | 2021-04-16 | 陕西天宇制药有限公司 | Polycinnamic alcohol external gel and preparation method thereof |
CN110496090B (en) * | 2019-09-26 | 2022-08-23 | 水羊化妆品制造有限公司 | Composition and application thereof to preparation of skin care product for repairing skin damaged all night |
MX2020013072A (en) | 2020-04-08 | 2022-01-24 | Beiersdorf Ag | Anti-pollution composition. |
EP4142692A2 (en) * | 2020-04-30 | 2023-03-08 | Blue Sky Innovation, LLC | Superoxide dismutase compositions and methods |
CN111514059B (en) * | 2020-05-26 | 2021-04-02 | 佛山市谷邦生物科技有限公司 | Ceramide compound skin-soothing moisturizing factor and facial mask thereof |
CN114624367B (en) * | 2020-12-14 | 2023-05-09 | 四川大学 | Method for extracting bamboo leaf flavone by adopting solid oxonium salt solvent-free pressurization |
CN113081897A (en) * | 2021-04-14 | 2021-07-09 | 刘继昌 | Medical ray skin antibacterial repairing agent |
WO2023057177A1 (en) | 2021-10-05 | 2023-04-13 | Beiersdorf Ag | Use of surfactants to provide a protective layer against pollution |
WO2023057134A1 (en) | 2021-10-05 | 2023-04-13 | Beiersdorf Ag | Rinse off anti-pollution emulsion |
WO2023057133A1 (en) | 2021-10-05 | 2023-04-13 | Beiersdorf Ag | Anti-pollution composition containing phenylbenzimidazol sulfonic acid |
WO2023057132A1 (en) | 2021-10-05 | 2023-04-13 | Beiersdorf Ag | Anti-pollution composition containing titanium dioxide |
WO2023057172A1 (en) | 2021-10-05 | 2023-04-13 | Beiersdorf Ag | Protection against pollution by polysaccharide gums |
CN114159462B (en) * | 2021-11-06 | 2023-02-03 | 中国人民解放军海军军医大学 | SiO 2 Application of the same in preparing anti-radiation medicine or medicine for treating ionizing radiation injury |
CN114569508A (en) * | 2022-03-14 | 2022-06-03 | 为美而生(广东)实业控股有限公司 | Moisturizing and skin-moistening facial cream containing collagen components and preparation method thereof |
CN115300580A (en) | 2022-04-25 | 2022-11-08 | 捷通国际有限公司 | Compositions and methods for inhibiting advanced glycation endproducts |
CN115040446A (en) * | 2022-06-24 | 2022-09-13 | 曾会明 | SOD plant extract skin care composition, skin care product and preparation method thereof |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5840681A (en) * | 1996-05-31 | 1998-11-24 | Thione International, Inc. | X-ray induced skin damage protective composition |
US6015548A (en) * | 1998-07-10 | 2000-01-18 | Shaklee Corporation | High efficiency skin protection formulation with sunscreen agents and antioxidants |
WO2001037788A1 (en) * | 1999-11-24 | 2001-05-31 | Alticor Inc. | Topical skin composition |
US20030095959A1 (en) * | 2000-11-21 | 2003-05-22 | Access Business Group International Llc. | Topical skin composition |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4637536A (en) * | 1985-08-14 | 1987-01-20 | Wilbur Wong | Personal binocular support |
IT1201151B (en) * | 1987-01-14 | 1989-01-27 | Indena Spa | PHOSPHOLIPID COMPLEXES WITH EXTRACTS FROM VITIS VINIFERA, PROCEDURE FOR THEIR PREPARATION AND COMPOSITIONS THAT CONTAIN THEM |
US5112814A (en) * | 1990-10-24 | 1992-05-12 | Robert Sabin | Method of treatment of Parkinson's disease using phytic acid |
US5378461A (en) * | 1991-07-12 | 1995-01-03 | Neigut; Stanley J. | Composition for the topical treatment of skin damage |
CA2089920C (en) * | 1992-02-21 | 1999-06-15 | John D. Johnston | Synergistic compositions for extending animal feed shelf life |
US5491651A (en) * | 1992-05-15 | 1996-02-13 | Key, Idea Development | Flexible wearable computer |
DE4228455A1 (en) * | 1992-08-26 | 1994-09-15 | Beiersdorf Ag | Cosmetic and dermatological sunscreen formulations containing thiols and / or thiol derivatives |
FR2704754B1 (en) * | 1993-05-07 | 1995-06-30 | Oreal | USE OF AN ALKYL ESTER OF GLUTATHION IN A COSMETIC OR DERMATOLOGICAL COMPOSITION FOR TOPICAL TREATMENT OF CUTANEOUS AGING. |
US5653970A (en) * | 1994-12-08 | 1997-08-05 | Lever Brothers Company, Division Of Conopco, Inc. | Personal product compositions comprising heteroatom containing alkyl aldonamide compounds |
FR2728790B1 (en) * | 1994-12-29 | 1997-01-24 | Cird Galderma | COMPOSITION MODULATING APOPTOSIS COMPRISING METHONIAL OR ANY FACTOR INFLUENCING THE INTRACELLULAR METHONIAL RATE |
US5866142A (en) * | 1995-07-20 | 1999-02-02 | Riordan; Neil H. | Skin treatment system |
US5683683A (en) * | 1995-09-21 | 1997-11-04 | Helene Curtis, Inc. | Body wash composition to impart conditioning properties to skin |
US6337320B1 (en) * | 1996-10-11 | 2002-01-08 | Thione International, Inc. | Reparatives for ultraviolet radiation skin damage |
US5804168A (en) * | 1997-01-29 | 1998-09-08 | Murad; Howard | Pharmaceutical compositions and methods for protecting and treating sun damaged skin |
US5935596A (en) * | 1997-03-20 | 1999-08-10 | Chesebrough-Pond's Usa Co. | Delivery of skin benefit agents via adhesive strips |
US6140981A (en) * | 1997-03-20 | 2000-10-31 | Kuenster; Gordon B. | Body-mountable display system |
US5902591A (en) * | 1997-04-03 | 1999-05-11 | La Prairie Sa | Stable topical cosmetic/pharmaceutical emulsion compositions containing ascorbic acid |
EP1011630B2 (en) * | 1997-09-12 | 2008-10-15 | The Procter & Gamble Company | Cleansing and conditioning article for skin or hair |
US5972985A (en) * | 1997-11-03 | 1999-10-26 | Cytos Pharmaceuticals, Llc | Histidine containing nutriceutical compositions |
US6093743A (en) * | 1998-06-23 | 2000-07-25 | Medinox Inc. | Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor |
US7854684B1 (en) * | 1998-06-24 | 2010-12-21 | Samsung Electronics Co., Ltd. | Wearable device |
US6184247B1 (en) * | 1999-05-21 | 2001-02-06 | Amway Corporation | Method of increasing cell renewal rate |
US6011067A (en) * | 1999-06-11 | 2000-01-04 | Thione International, Inc. | Antioxidant composition for the treatment of psoriasis and related diseases |
US6521668B2 (en) * | 1999-12-14 | 2003-02-18 | Avon Products, Inc. | Cosmetic composition and methods of use |
EP1166225A1 (en) * | 2000-01-31 | 2002-01-02 | Collaborative Technologies, Inc. | Method and system for producing customized cosmetic and pharmaceutical formulations on demand |
AU2002331001A1 (en) * | 2001-08-07 | 2003-02-24 | Dow Corning Corporation | Hair and skin care compositions containing siloxane-based polyamide copolymers |
-
2006
- 2006-07-31 US US11/497,152 patent/US20070003536A1/en not_active Abandoned
- 2006-12-29 US US11/617,884 patent/US20080081034A1/en not_active Abandoned
- 2006-12-29 US US11/617,871 patent/US20080081082A1/en not_active Abandoned
-
2007
- 2007-07-27 CN CNA2007800366849A patent/CN101522265A/en active Pending
- 2007-07-27 KR KR1020097003288A patent/KR20090040344A/en not_active Application Discontinuation
- 2007-07-27 WO PCT/US2007/074551 patent/WO2008016842A1/en active Application Filing
- 2007-07-27 CN CNA2007800367184A patent/CN101522266A/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5840681A (en) * | 1996-05-31 | 1998-11-24 | Thione International, Inc. | X-ray induced skin damage protective composition |
US6015548A (en) * | 1998-07-10 | 2000-01-18 | Shaklee Corporation | High efficiency skin protection formulation with sunscreen agents and antioxidants |
WO2001037788A1 (en) * | 1999-11-24 | 2001-05-31 | Alticor Inc. | Topical skin composition |
US20030095959A1 (en) * | 2000-11-21 | 2003-05-22 | Access Business Group International Llc. | Topical skin composition |
Non-Patent Citations (1)
Title |
---|
MONTENEGRO L. ET AL.: "Protective effect evaluation of free radical scavengers on UVB induced human cutaneous erythema by skin reflectance spectrophotometry", INTERNATIONAL JOURNAL OF COSMETIC SCIENCE, vol. 17, 1995, pages 91 - 103, XP009052473 * |
Also Published As
Publication number | Publication date |
---|---|
US20080081034A1 (en) | 2008-04-03 |
CN101522265A (en) | 2009-09-02 |
CN101522266A (en) | 2009-09-02 |
KR20090040344A (en) | 2009-04-23 |
US20080081082A1 (en) | 2008-04-03 |
US20070003536A1 (en) | 2007-01-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20070003536A1 (en) | Topical skin compositions, their preparation, and their use | |
US20080124409A1 (en) | Topical Skin Compositions, Their Preparation, and Their Use | |
US20030095959A1 (en) | Topical skin composition | |
US9585822B2 (en) | Methods of preparing and using botanical antioxidant compositions | |
EP2265249B1 (en) | Cosmetic compositions comprising exopolysaccharides derived from microbial mats, and use thereof | |
AU2004323347B2 (en) | Topical compositions containing phosphorylated polyphenols | |
WO2001037788A1 (en) | Topical skin composition | |
KR101275971B1 (en) | Composition for antioxidation effect comprising sparassis crispa extract | |
JP2021532064A (en) | Composition containing dendrobium nobile and its usage | |
AU2002360571B2 (en) | Methods for improving the aesthetic appearance of skin | |
EP1390008A2 (en) | Pharmaceutical and cosmetic compositions against skin aging | |
AU2002342279A1 (en) | Pharmaceutical and cosmetic compositions against skin aging | |
AU2009238172B2 (en) | Cosmetic compositions comprising exopolysaccharides derived from microbial mats, and use thereof | |
Shimoda | Food-derived materials improving skin cell health for smoother skin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200780036718.4 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07799874 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020097003288 Country of ref document: KR |
|
NENP | Non-entry into the national phase |
Ref country code: RU |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 07799874 Country of ref document: EP Kind code of ref document: A1 |